Showing results (1311-1320 of 1,547) with videos related to
Sort By:
Pageof 155
Neuro-Oncology|October 25, 2025
Associations of supramaximal resection with outcome in glioblastoma across age groups: a report of the RANO resect groupNico Teske, Antonio Dono, Jacob S Young, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Central nervous system cancersLouis Burt Nabors, Mario Ammirati, Philip J Bierman, et al.The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.Neuro-Oncology|August 12, 2021
Multimodal platform for assessing drug distribution and response in clinical trialsBegoña G C Lopez, Ishwar N Kohale, Ziming Du, et al.Nature Cancer|June 3, 2026
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastomaJack Y Ghannam, Julian Bryan, Jakob Weiss, et al.Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.Neuro-Oncology|August 20, 2024
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumorsHia S Ghosh, Ruchit V Patel, Eleanor Woodward, et al.The Lancet. Oncology|June 13, 2015
Response assessment criteria for brain metastases: proposal from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.Cancer Cell|April 5, 2024
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendrogliomaAvishay Spitzer, Simon Gritsch, Masashi Nomura, et al.Pageof 155